Jorien van der Schaft - JoVE Visualize

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of the American Academy of Dermatology|September 18, 2020

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Lotte S Spekhorst, et al.

Allergy|October 9, 2019

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, et al.

Journal of the American Academy of Dermatology|August 15, 2017

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema CouncilEric L Simpson, Marjolein Bruin-Weller, Carsten Flohr, et al.

Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of the American Academy of Dermatology|September 18, 2020

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Lotte S Spekhorst, et al.

Allergy|October 9, 2019

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, et al.

Journal of the American Academy of Dermatology|August 15, 2017

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema CouncilEric L Simpson, Marjolein Bruin-Weller, Carsten Flohr, et al.

Pageof 2